炎症相关基因PLA2G7和TNF与冠心病的关联研究
|
摘要
第一部分:PLA2G7
脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,Lp-PLA_2)是心血管疾病中一种新的炎症标记物,由PLA2G7基因编码。本研究中,我们从中国汉族人群中选取827例冠心病病例(包括512例心肌梗死病例)和947例年龄和性别匹配的对照,对PLA2G7基因中的8个单核苷酸多态性(single nucleotidepolymorphism,SNP)位点进行了基因分型。我们随机挑选了416例对照和689例冠心病病例(包括423例心肌梗死病例)进行血浆Lp-PLA_2活性的测定。结果显示冠心病组和心肌梗死组Lp-PLA_2活性(233.42±57.66和234.27±59.51 nmol/ml/min)显著高于对照组(211.47±58.61 nmol/ml/min)。使用logistic回归校正传统危险因素后,Lp-PLA_2活性每增加一个标准差,冠心病和心肌梗死的比值比分别为1.27(95%CI,1.07～1.50)和1.27(95%CI,1.05～1.54)。单点分析和单体型分析提示V279F和I198T多态与Lp-PLA_2的活性下降有关,但这两个SNP位点与冠心病之间不存在显著的关联。单变量和多变量分析均提示rs13210554多态的T等位基因增加中国汉族人群心肌梗死的患病风险。总之,本研究提示血浆Lp-PLA_2活性与中国汉族人群冠心病和心肌梗死独立相关。V279F和I198T多态显著降低Lp-PLA_2的活性,位于启动子区的rs13210554多态与心肌梗死显著关联。Lp-PLA_2活性可能影响中国汉族人群冠心病和心肌梗死的患病风险。
第二部分:TNF
肿瘤坏死因子α(tumor necrosis factor alpha,TNF-α)是一个主要的促炎细胞因子,可能参与心血管疾病的发病过程。TNF基因多态位点与冠心病的关联研究已有报道,但研究结果很不一致。本研究拟在中国汉族人群中全面分析TNF基因遗传变异与冠心病的关系。为发现新的SNP多态位点,随机挑选了48例冠心病病例,对包含TNF基因编码区及上下游各约1kb的4739个碱基对的区域进行了重测序。从7个发现的SNP位点中选择4个(-806C＞T、-308G＞A、-238G＞A和+467G＞A),在804例冠心病病例(包括504例心肌梗死病例)和905例年龄和性别匹配的对照中进行了基因分型,进一步分析这些SNP位点与冠心病易感性间的关系。在整个样本中进行的分析未发现单个位点及单体型与冠心病存在显著的关联。但是,我们发现基因与吸烟之间存在显著的交互作用。在不吸烟个体中,与G/G基因型纯合子个体相比,-238G＞A多态的A等位基因携带者具有较低的冠心病患病风险(比值比0.48,95%CI 0.24～0.94,P=0.033),心肌梗死的患病风险更低(比值比0.36,95%CI 0.15～0.88,P=0.026)。单体型分析进一步证实了单点分析的结果。另外,我们还发现在吸烟个体当中-806C＞T多态与心肌梗死存在显著的关联(P=0.039)。总之,本研究发现TNF基因与吸烟之间存在显著的交互作用。单点分析和单体型分析均提示-238G＞A多态的A等位基因能降低中国汉族人群不吸烟个体冠心病的患病风险。
Section one:PLA2G7
The human PLA2G7 gene encodes lipoprotein-associated phospholipase A2(Lp-PLA_2), an emerging risk factor for cardiovascular diseases.In the present study,eight single nucleotide polymorphisms(SNPs) in the PLA2G7 gene were genotyped in 827 patients with coronary heart disease(CHD),of which 512 were patients with myocardial infarction(MI),and 947 age- and gender-matched controls in a Chinese Han population. Plasma Lp-PLA_2 activity was measured in 416 randomly selected controls and 689 randomly selected CHD patients,including 423 MI patients.Lp-PLA_2 activity in CHD and MI cases was significantly higher(233.42±57.66 and 234.27±59.51 nmol/ml/min,respectively) than in controls(211.47±58.61 nmol/ml/min).After adjusting for traditional risk factors by logistic regression,the odds ratios for CHD and MI per 1 standard deviation increment of Lp-PLA_2 activity were 1.27(95%CI,1.07-1.50) and 1.27(95%CI, 1.05-1.54),respectively.Both single SNP analysis and haplotype analysis showed that the V279F and I198T polymorphisms were significantly associated with the reduced Lp-PLA_2 activity but neither was associated with increased CHD risk.Both univariate and multivariate analyses,adjusting effects of conventional factors,indicated that the rs13210554 T allele increased the risk of MI in this Chinese Hart population.In summary,an independent association of increased plasma Lp-PLA_2 activity with CHD and MI existed in this Chinese Han Population.Although V279F and I198T mutations significantly decreased the activity of Lp-PLA_2,only the promoter rs13210554 polymorphism was associated with MI. Lp-PLA_2 activity appears to influence the CHD and MI risk in Chinese Han population.
Section two:TNF
Tumor necrosis factor alpha(TNF-α) is a primary pro-inflammatory cytokines and has been implicated in cardiovascular disease pathogenesis.Relationship between polymorphisms in TNF gene and CHD has been reported,but remains a controversial one.A single nucleotide polymorphism(SNP) discovery in a total of 4739 base pairs in the promoter region,exon region and exon/intron boarding region of TNF gene in randomly selected 48 patients by direct sequencing was conducted.Four SNPs(-806C＞T,-308G＞A, -238G＞A,and +467G＞A) out of seven polymorphisms identified were further investigated for associations in 804 CHD patients(of which 504 patients with MI) and 905 age-and gender-matched controls.No main effects of loci and haplotypes reached statistical significance in the total sample.However,a significant gene-smoking interaction was observed. In nonsmokers,compared with individuals of G/G genotype,individuals carrying the A allele of the -238G＞A polymorphism showed a lower risk of developing CHD(odds ratio 0.48,95%CI 0.24-0.94,P=0.033),and an even lower risk of developing MI(odds ratio 0.36,95%CI 0.15-0.88,P=0.026).Haplotype analysis confirmed the results of individual polymorphism analyses.In addition,the -806C＞T polymorphism was found to be associated with MI in smokers(P=0.039).This study identified a significant interaction between TNF gene and smoking status.Both single locus and haplotype analyses indicated that A allele of the -238G＞A polymorphism decreased the risk of CHD among nonsmokers in Chinese Han population.
脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,Lp-PLA_2)是心血管疾病中一种新的炎症标记物,由PLA2G7基因编码。本研究中,我们从中国汉族人群中选取827例冠心病病例(包括512例心肌梗死病例)和947例年龄和性别匹配的对照,对PLA2G7基因中的8个单核苷酸多态性(single nucleotidepolymorphism,SNP)位点进行了基因分型。我们随机挑选了416例对照和689例冠心病病例(包括423例心肌梗死病例)进行血浆Lp-PLA_2活性的测定。结果显示冠心病组和心肌梗死组Lp-PLA_2活性(233.42±57.66和234.27±59.51 nmol/ml/min)显著高于对照组(211.47±58.61 nmol/ml/min)。使用logistic回归校正传统危险因素后,Lp-PLA_2活性每增加一个标准差,冠心病和心肌梗死的比值比分别为1.27(95%CI,1.07～1.50)和1.27(95%CI,1.05～1.54)。单点分析和单体型分析提示V279F和I198T多态与Lp-PLA_2的活性下降有关,但这两个SNP位点与冠心病之间不存在显著的关联。单变量和多变量分析均提示rs13210554多态的T等位基因增加中国汉族人群心肌梗死的患病风险。总之,本研究提示血浆Lp-PLA_2活性与中国汉族人群冠心病和心肌梗死独立相关。V279F和I198T多态显著降低Lp-PLA_2的活性,位于启动子区的rs13210554多态与心肌梗死显著关联。Lp-PLA_2活性可能影响中国汉族人群冠心病和心肌梗死的患病风险。
第二部分:TNF
肿瘤坏死因子α(tumor necrosis factor alpha,TNF-α)是一个主要的促炎细胞因子,可能参与心血管疾病的发病过程。TNF基因多态位点与冠心病的关联研究已有报道,但研究结果很不一致。本研究拟在中国汉族人群中全面分析TNF基因遗传变异与冠心病的关系。为发现新的SNP多态位点,随机挑选了48例冠心病病例,对包含TNF基因编码区及上下游各约1kb的4739个碱基对的区域进行了重测序。从7个发现的SNP位点中选择4个(-806C＞T、-308G＞A、-238G＞A和+467G＞A),在804例冠心病病例(包括504例心肌梗死病例)和905例年龄和性别匹配的对照中进行了基因分型,进一步分析这些SNP位点与冠心病易感性间的关系。在整个样本中进行的分析未发现单个位点及单体型与冠心病存在显著的关联。但是,我们发现基因与吸烟之间存在显著的交互作用。在不吸烟个体中,与G/G基因型纯合子个体相比,-238G＞A多态的A等位基因携带者具有较低的冠心病患病风险(比值比0.48,95%CI 0.24～0.94,P=0.033),心肌梗死的患病风险更低(比值比0.36,95%CI 0.15～0.88,P=0.026)。单体型分析进一步证实了单点分析的结果。另外,我们还发现在吸烟个体当中-806C＞T多态与心肌梗死存在显著的关联(P=0.039)。总之,本研究发现TNF基因与吸烟之间存在显著的交互作用。单点分析和单体型分析均提示-238G＞A多态的A等位基因能降低中国汉族人群不吸烟个体冠心病的患病风险。
Section one:PLA2G7
The human PLA2G7 gene encodes lipoprotein-associated phospholipase A2(Lp-PLA_2), an emerging risk factor for cardiovascular diseases.In the present study,eight single nucleotide polymorphisms(SNPs) in the PLA2G7 gene were genotyped in 827 patients with coronary heart disease(CHD),of which 512 were patients with myocardial infarction(MI),and 947 age- and gender-matched controls in a Chinese Han population. Plasma Lp-PLA_2 activity was measured in 416 randomly selected controls and 689 randomly selected CHD patients,including 423 MI patients.Lp-PLA_2 activity in CHD and MI cases was significantly higher(233.42±57.66 and 234.27±59.51 nmol/ml/min,respectively) than in controls(211.47±58.61 nmol/ml/min).After adjusting for traditional risk factors by logistic regression,the odds ratios for CHD and MI per 1 standard deviation increment of Lp-PLA_2 activity were 1.27(95%CI,1.07-1.50) and 1.27(95%CI, 1.05-1.54),respectively.Both single SNP analysis and haplotype analysis showed that the V279F and I198T polymorphisms were significantly associated with the reduced Lp-PLA_2 activity but neither was associated with increased CHD risk.Both univariate and multivariate analyses,adjusting effects of conventional factors,indicated that the rs13210554 T allele increased the risk of MI in this Chinese Hart population.In summary,an independent association of increased plasma Lp-PLA_2 activity with CHD and MI existed in this Chinese Han Population.Although V279F and I198T mutations significantly decreased the activity of Lp-PLA_2,only the promoter rs13210554 polymorphism was associated with MI. Lp-PLA_2 activity appears to influence the CHD and MI risk in Chinese Han population.
Section two:TNF
Tumor necrosis factor alpha(TNF-α) is a primary pro-inflammatory cytokines and has been implicated in cardiovascular disease pathogenesis.Relationship between polymorphisms in TNF gene and CHD has been reported,but remains a controversial one.A single nucleotide polymorphism(SNP) discovery in a total of 4739 base pairs in the promoter region,exon region and exon/intron boarding region of TNF gene in randomly selected 48 patients by direct sequencing was conducted.Four SNPs(-806C＞T,-308G＞A, -238G＞A,and +467G＞A) out of seven polymorphisms identified were further investigated for associations in 804 CHD patients(of which 504 patients with MI) and 905 age-and gender-matched controls.No main effects of loci and haplotypes reached statistical significance in the total sample.However,a significant gene-smoking interaction was observed. In nonsmokers,compared with individuals of G/G genotype,individuals carrying the A allele of the -238G＞A polymorphism showed a lower risk of developing CHD(odds ratio 0.48,95%CI 0.24-0.94,P=0.033),and an even lower risk of developing MI(odds ratio 0.36,95%CI 0.15-0.88,P=0.026).Haplotype analysis confirmed the results of individual polymorphism analyses.In addition,the -806C＞T polymorphism was found to be associated with MI in smokers(P=0.039).This study identified a significant interaction between TNF gene and smoking status.Both single locus and haplotype analyses indicated that A allele of the -238G＞A polymorphism decreased the risk of CHD among nonsmokers in Chinese Han population.
引文
[1]Hansson GK.Inflammation,atherosclerosis,and coronary artery disease[J].N Engl J Med,2005;352(16):1685-1695.
[2]Kolodgie FD,Burke AP,Skorija KS,Ladich E,Kutys R,Makuria AT,et al.Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis [J].Arterioscler Thromb Vase Biol,2006;26(11):2523-2529.
[3]Stafforini DM,Numao T,Tsodikov A,Vaitkus D,Fukuda T,Watanabe N,et al.Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma[J].J Clin Invest,1999;103(7):989-997.
[4]H(a|¨)kkinen T,Luoma JS,Hiltunen MO,Macphee CH,Milliner KJ,Patel L,et al.Lipoprotein-associated phospholipase A(2),platelet-activating factor acetylhydrolase,is expressed by macrophages in human and rabbit atherosclerotic lesions[J].Arterioscler Thromb Vase Biol,1999;19(12):2909-2917.
[5]Ballantyne CM,Hoogeveen RC,Bang H,Coresh J,Folsom AR,Heiss G,et al.Lipoprotein-associated phospholipase A2,high-sensitivity C-reactive protein,and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC)study[J].Circulation,2004;109(7):837-842.
[6]Koenig W,Twardella D,Brenner H,Rothenbacher D.Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors,markers of inflammation,renal function,and hemodynamic stress[J].Arterioscler Thromb Vase Biol,2006;26(7):1586-1593.
[7]Oei HH,van der Meer JJM,Hofman A,Koudstaal PJ,Stijnen T,Breteler MMB,et al.Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke:the Rotterdam Study [J].Circulation,2005;111(5):570-575.
[8]Packard CJ,O'Reilly DS,Caslake MJ,McMahon AD,Ford I,Cooney J,et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.West of Scotland Coronary Prevention Study Group[J].N Engl J Med,2000;343(16):1148-1155.
[9]Sabatine MS,Morrow DA,O'Donoghue M,Jablonksi KA,Rice MM,Solomon S,et al.Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease [J].Arterioscler Thromb Vasc Biol,2007;27(11):2463-2469.
[10]Yamada Y,Ichihara S,Fujimura T,Yokota M.Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men [J].Metabolism,1998;47(2):177-181.
[11]Yamada Y,Yoshida H,Ichihara S,Imaizumi T,Satoh K,Yokota M.Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH)activity and PAFAH genotype,age,and atherosclerosis in a Japanese population[J].Atherosclerosis,2000;150(1):209-216.
[12]Zhang SY,Shibata H,Karino K,Wang BY,Kobayashi S,Masuda J,et al.Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population[J].Hypertens Res,2007;30(5):403-409.
[13]Hiramoto M,Yoshida H,Imaizumi T,Yoshimizu N,Satoh K.A mutation in plasma platelet-activating factor acetylhydrolase (Va1279→Phe)is a genetic risk factor for stroke[J].Stroke,1997;28(12):2417-2420.
[14]Jang Y,Kim OY,Koh SJ,Chae JS,Ko YG,Kim JY,et al.The Va1279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men[J].J Clin Endocrinol Metab,2006;91(9):3521-3527.
[15]Abuzeid AM,Hawe E,Humphries SE,Talmud PJ,Group HIFMECHS.Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe[J].Atherosclerosis,2003;168(2):283-288.
[16]Ninio E,Tregouet D,Carrier JL,Stengel D,Bickel C,Perret C,et al.Plateletactivating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease [J].Hum Mol Genet,2004;13(13):1341-1351.
[17]Kruse S,Mao XQ,Heinzmann A,Blattmann S,Roberts MH,Braun S,et al.The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma[J].Am J Hum Genet,2000;66(5):1522-1530.
[18]Wootton PT,Stephens JW,Hurel SJ,Durand H,Cooper J,Ninio E,et al.Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus[J].Atherosclerosis,2006;189(1):149-156.
[19]Schaid DJ,Rowland CM,Tines DE,Jacobson RM,Poland GA.Score tests for association between traits and haplotypes when linkage phase is ambiguous[J].Am J Hum Genet,2002;70(2):425-434.
[20]Persson M,Hedblad B,Nelson J J,Berglund G.Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects[J].Arterioscler Thromb Vase Biol,2007;27(6):1411-1416.
[21]Saougos VG,Tambaki AP,Kalogirou M,Kostapanos M,Gazi IF,Wolfert RL,et al.Differential effect of hypolipidemic drugs on lipoprotein-associated phosphohpase A2[J].Arterioscler Thromb Vase Biol,2007;27(10):2236-2243.
[22]Ross R.Atherosclerosis-an inflammatory disease[J].N Engl J Med,1999;340(2):115-126.
[23]Macphee CH.Lipoprotein-associated phosphohpase A2:a potential new risk factor for coronary artery disease and a therapeutic target[J].Curr Opin Pharmacol,2001;1(2):121-125.
[24]Brilakis ES,Khera A,McGuire DK,See R,Banerjee S,Murphy SA,et al.Influence of race and sex on lipoprotein-associated phosphohpase A2 levels:observations from the Dallas Heart Study[J].Atherosclerosis,2008;199(1):110-115.
[25]Sutton BS,Crosslin DR,Shah SH,Nelson SC,Bassil A,Hale AB,et al.Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7)gene and cardiovascular disease in case-control and family datasets[J].Hum Mol Genet,2008;17(9):1318-1328.
[26]Liu PY,Li YH,Wu HL,Chao TH,Tsai LM,Lin LJ,et al.Platelet-activating factoracetylhydrolase A379V (exon 11)gene polymorphism is an independent and func- tional risk factor for premature myocardial infarction[J].J Thromb Haemost,2006;4(5):1023-1028.
[27]Zondervan KT,Cardon LR.The complex interplay among factors that influence allelic association[J].Nat Rev Genet,2004;5(2):89-100.
[1]Bemelmans MH,van Tits LJ,Buurman WA.Tumor necrosis factor:function,release and clearance[J].Crit Rev Immunol,1996;16(1):1-11.
[2]Bochner BS,Luscinskas FW,Gimbrone MA,Newman W,Sterbinsky SA,Derse-Anthony CP,et al.Adhesion of human basophils,eosinophils,and neutrophils to interleukin 1-activated human vascular endothelial cells:contributions of endothelial cell adhesion molecules [J].J Exp Med,1991;173(6):1553-1557.
[3]Mantovani A.The interplay between primary and secondary cytokines.Cytokines involved in the regulation of monocyte recruitment[J].Drugs,1997;54 Suppl 1:15-23.
[4]Castell JV,Andus T,Kunz D,Heinrich PC.Interleukin-6.The major regulator of acute-phase protein synthesis in man and rat [J].Ann N Y Acad Sci,1989;557:87-99.
[5]Siwik DA,Chang DL,Colucci WS.Interleukin-1 beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro[J].Circ Res,2000;86(12):1259-1265.
[6]KahaFri VM,Chen YQ,Su MW,Ramirez F,Uitto J.Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1.Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels [J].J Clin Invest,1990;86(5):1489-1495.
[7]Zhang C,Zhang MX,Shen YH,Burks JK,Zhang Y,Wang J,et al.TNF-alpha suppresses prolyl-4-hydroxylase alphal expression via the ASKl-JNK-NonO pathway[J].Arterioscler Thromb Vase Biol,2007;27(8):1760-1767.
[8]Feingold KR,Grunfeld C.Role of cytokines in inducing hyperlipidemia[J].Diabetes,1992;41 Suppl 2:97-101.
[9]Hotamisligil GS,Shargill NS,Spiegelman BM.Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance [J].Science,1993;259(5091):87-91.
[10]Cesari M,Penninx BWJH,Newman AB,Kritchevsky SB,Nicklas BJ,Sutton-Tyrrell K,et al.Inflammatory markers and onset of cardiovascular events:results from the Health ABC study[JJ.Circulation,2003;108(19):2317-2322.
[11]Ridker PM,Rifai N,Pfeffer M,Sacks F,Lepage S,Braunwald E.Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction[J].Circulation,2000;101(18):2149-2153.
[12]Khot UN,Khot MB,Bajzer CT,Sapp SK,Ohman EM,Brener SJ,et al.Prevalence of conventional risk factors in patients with coronary heart disease[J].JAMA,2003;290(7):898-904.
[13]Haddy N,Sass C,Droesch S,Zaiou M,Siest G,Ponthieux A,et al.IL-6,TNF-alpha and atherosclerosis risk indicators in a healthy family population:the STANISLAS cohort[J].Atherosclerosis,2003;170(2):277-283.
[14]Abraham LJ,Kroeger KM.Impact of the-308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene:relevance to disease[J].J Leukoc Biol,1999;66(4):562-566.
[15]Kaluza W,Reuss E,Grossmann S,Hug R,Schopf RE,Galle PR,et al.Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism[J].J Invest Dermatol,2000;114(6):1180-1183.
[16]Hakkinen T,Luoma JS,Hiltunen MO,Macphee CH,Milliner KJ,Patel L,et al.Lipoprotein-associated phospholipase A(2),platelet-activating factor acetylhydrolase,is expressed by macrophages in human and rabbit atherosclerotic lesions [J].Arterioscler Thromb Vase Biol,1999;19(12):2909-2917.
[17]Szalai C,Fixst G,Duba J,Kramer J,Romics L,Prohdszka Z,et al.Association of polymorphisms and allelic combinations in the tumour necrosis factor-alphacomplement MHC region with coronary artery disease [J].J Med Genet,2002;39(1):46-51.
[18]Bidwell J,Keen L,Gallagher G,Kimberly R,Huizinga T,McDermott MF,et al.Cytokine gene polymorphism in human disease:on-line databases[J].Genes Immun,1999;1(1):3-19.
[19]Schaid DJ,Rowland CM,Tines DE,Jacobson RM,Poland GA.Score tests for association between traits and haplotypes when linkage phase is ambiguous[J].Am J Hum Genet,2002;70(2):425-434.
[20]Ackerman H,Usen S,Mott R,Richardson A,Sisay-Joof F,Katundu P,et al.Haplotypic analysis of the TNF locus by association efficiency and entropy [J].Genome Biol,2003;4(4):R24.
[21]Furuta M,Yano Y,Ito K,Gabazza EC,Katsuki A,Tanaka T,et al.Relationship of the tumor necrosis factor-alpha-308 A/G promoter polymorphism with insulin sensitivity and abdominal fat distribution in Japanese patients with type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2002;56(2):141-145.
[22]D'Alfonso S,Richiardi PM.A polymorphic variation in a putative regulation box of the TNFA promoter region [J].Immunogenetics,1994;39(2):150-154.
[23]Day CP,Grove J,Daly AK,Stewart MW,Avery PJ,Walker M.Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance[J].Diabetologia,1998;41(4):430-434.
[24]Culpan D,MacGowan SH,Ford JM,Nicoll JAR,Griffin WS,Dewar D,et al.Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease[J].Neurosci Lett,2003;350(1):61-65.
[25]Allen RA,Lee EM,Roberts DH,Park BK,Pirmohamed M.Polymorphisms in the TNF-alpha and TNF-receptor genes in patients with coronary artery disease[J].Eur J Clin Invest,2001;31(10):843-851.
[26]Vendrell J,Fernandez-Real JM,Gutierrez C,Zamora A,Simon I,Bardaji A,et al.A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308)is associated with coronary heart disease in type 2 diabetic patients[J].Atherosclerosis,2003;167(2):257-264.
[27]Bennet AM,van Maarle MC,Hallqvist J,Morgenstem R,Frostegard J,Wiman B,et al.Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction [J].Atherosclerosis,2006;187(2):408-414.
[28]Lee YH,Harley JB,Nath SK.Meta-analysis of TNF-alpha promoter-308 A/G polymorphism and SLE susceptibility [J].Eur J Hum Genet,2006;14(3):364-371.
[29]Wei Q,Doris PA,Pollizotto MV,Boerwinkle E,Jacobs DR,Siscovick DS,et al.Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis:interaction with cigarette smoking[J].Atherosclerosis,2007;190(1):26-34.
[1]Gu D,Reynolds K,Wu X,Chen J,Duan X,Muntner P,et al.Prevalence,awareness,treatment,and control of hypertension in china[J].Hypertension,2002;40(6):920-927.
[2]Libby P,Theroux P.Pathophysiology of coronary artery disease[J].Circulation,2005;111(25):3481-3488.
[3]Glagov S,Weisenberg E,Zarins CK,Stankunavicius R,Kolettis GJ.Compensatory enlargement of human atherosclerotic coronary arteries[J].N Engl J Med,1987;316(22):1371-1375.
[4]Clarkson TB,Prichard RW,Morgan TM,Petrick GS,Klein KP.Remodeling of coronary arteries in human and nonhuman primates[J].JAMA,1994;271(4):289-294.
[5]Tuzcu EM,Kapadia SR,Tutar E,Ziada KM,Hobbs RE,McCarthy PM,et al.High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults:evidence from intravascular ultrasound [J].Circulation,2001;103(22):2705-2710.
[6]Yokoya K,Takatsu H,Suzuki T,Hosokawa H,Ojio S,Matsubara T,et al.Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis:A study based on four serial coronary arteriograms per year[J].Circulation,1999;100(9):903-909.
[7]Falk E,Shah PK,Fuster V.Coronary plaque disruption [J].Circulation,1995;92(3):657-671.
[8]Virmani R,Burke AP,Farb A,Kolodgie FD.Pathology of the unstable plaque[J].Prog Cardiovasc Dis,2002;44(5):349-356.
[9]Libby P.Inflammation in atherosclerosis[J].Nature,2002;420(6917):868-874.
[10]Gimbrone MA.Vascular endothelium,hemodynamic forces,and atherogenesis[J].Am J Pathol,1999;155(1):1-5.
[11]Li H,Cybulsky MI,Gimbrone MA,Libby P.An atherogenic diet rapidly induces VCAM-1,a cytokine-regulatable mononuclear leukocyte adhesion molecule,in rabbit aortic endothelium [J].Arterioscler Thromb,1993;13(2):197-204.
[12]Collins T,Cybulsky MI.NF-kappaB:pivotal mediator or innocent bystander in atherogenesis[J]? J Clin Invest,2001;107(3):255-264.
[13]Gu L,Okada Y,Clinton SK,Gerard C,Sukhova GK,Libby P,et al.Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice[J].Mol Cell,1998;2(2):275-281.
[14]Boring L,Gosling J,Cleary M,Charo IF.Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis [J].Nature,1998;394(6696):894-897.
[15]Cyrus T,Witztum JL,Rader DJ,Tangirala R,Fazio S,Linton MF,et al.Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice[J].J Clin Invest,1999;103(11):1597-1604.
[16]Shih DM,Xia YR,Wang XP,Miller E,Castellani LW,Subbanagounder G,et al.Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis[J].J Biol Chem,2000;275(23):17527-17535.
[17]Suzuki H,Kurihara Y,Takeya M,Kamada N,Kataoka M,Jishage K,et al.A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection[J].Nature,1997;386(6622):292-296.
[18]Febbraio M,Podrez EA,Smith JD,Hajjar DP,Hazen SL,Hoff HF,et al.Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice[J].J Clin Invest,2000;105(8):1049-1056.
[19]Schonbeck U,Sukhova GK,Shimizu K,Mach F,Libby P.Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice[J].Proc Natl Acad Sci U S A,2000;97(13):7458-7463.
[20]Lange LA,Carlson CS,Hindorff LA,Lange EM,Walston J,Durda JP,et al.Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events[J].JAMA,2006;296(22):2703-2711.
[21]Reiner AP,Barber MJ,Guan Y,Ridker PM,Lange LA,Chasman DI,et al.Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein[J].Am J Hum Genet,2008;82(5):1193-1201.
[22]Ridker PM,Pare G,Parker A,Zee RYL,Danik JS,Buring JE,et al.Loci related to metabolic-syndrome pathways including LEPR,HNF1 A,IL6R,and GCKR associate with plasma C-reactive protein:the Women's Genome Health Study [J].Am J Hum Genet,2008;82(5):1185-1192.
[23]Erdmann J,Grosshennig A,Braund PS,Konig IR,Hengstenberg C,Hall AS,et al.New susceptibility locus for coronary artery disease on chromosome 3q22.3[J].Nat Genet,2009;41(3):280-282.
[24]Ridker PM,Cannon CP,Morrow D,Rifai N,Rose LM,McCabe CH,et al.Creactive protein levels and outcomes after statin therapy [J].N Engl J Med,2005;352(1 ):20-28.
[25]Cook NR,Buring JE,Ridker PM.The effect of including C-reactive protein in cardiovascular risk prediction models for women[J].Ann Intern Med,2006;145(1):21-29.
[26]Ridker PM,Paynter NP,Rifai N,Gaziano JM,Cook NR.C-reactive protein and parental history improve global cardiovascular risk prediction:the Reynolds Risk Score for men[J].Circulation,2008;118(22):2243-51,4p following 2251.
[27]Caslake MJ,Packard CJ,Suckling KE,Holmes SD,Chamberlain P,Macphee CH.Lipoprotein-associated phospholipase A(2),platelet-activating factor acetylhydrolase:a potential new risk factor for coronary artery disease[J].Atherosclerosis,2000;150(2):413-419.
[28]Manya H,Aoki J,Kato H,Ishii J,Hino S,Arai H,et al.Biochemical characterization of various catalytic complexes of the brain platelet-activating factor acetylhydrolase[J].J Biol Chem,1999;274(45):31827-31832.
[29]Watson AD,Navab M,Hama SY,Sevanian A,Prescott SM,Stafforini DM,et al.Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein [J].J Clin Invest,1995;95(2):774-782.
[30]Macphee CH,Nelson J,Zalewski A.Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target[J].Curr Opin Pharmacol,2006;6(2):154-161.
[31]Zalewski A,Macphee C.Role of lipoprotein-associated phospholipase A2 in atherosclerosis:biology,epidemiology,and possible therapeutic target[J].Arterioscler Thromb Vase Biol,2005;25(5):923-931.
[32]Packard CJ,O'Reilly DS,Caslake MJ,McMahon AD,Ford I,Cooney J,et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.West of Scotland Coronary Prevention Study Group[J].N Engl J Med,2000;343(16):1148-1155.
[33]Koenig W,Khuseyinova N,Lowel H,Trischler G,Meisinger C.Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population:results from the 14-year follow-up of a large cohort from southern Germany [J].Circulation,2004;110(14):1903-1908.
[34]Brilakis ES,McConnell JP,Lennon RJ,Elesber AA,Meyer JG,Berger PB.Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors,angiographic coronary artery disease,and major adverse events at follow-up[J].Eur Heart J,2005;26(2):137-144.
[35]Koenig W,Twardella D,Brenner H,Rothenbacher D.Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors,markers of inflammation,renal function,and hemodynamic stress[J].Arterioscler Thromb Vase Biol,2006;26(7):1586-1593.
[36]O'Donoghue M,Morrow DA,Sabatine MS,Murphy SA,McCabe CH,Cannon CP,et al.Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)trial[J].Circulation,2006;113(14):1745-1752.
[37]Jang Y,Kim OY,Koh SJ,Chae JS,Ko YG,Kim JY,et al.The Va1279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men[J].J Clin Endocrinol Metab,2006;91(9):3521-3527.
[38]Hou L,Chen S,Yu H,Lu X,Chen J,Wang L,et al.Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population:the Beijing atherosclerosis study[J].Hum Genet,2009;125(1):11-20.
[39]Sekuri C,Cam FS,Tengiz I,Ercan E,Bayturan O,Berdeli A.Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coro- nary artery disease in Turkish patients[J].Anadolu Kardiyol Derg,2006;6(2):132-134.
[40]Kruse S,Mao XQ,Heinzmann A,Blattmann S,Roberts MH,Braun S,et al.The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma[J].Am J Hum Genet,2000;66(5):1522-1530.
[41]Abuzeid AM,Hawe E,Humphries SE,Talmud PJ,Group HIFMECHS.Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe[J].Atherosclerosis,2003;168(2):283-288.
[42]Ninio E,Tregouet D,Carrier JL,Stengel D,Bickel C,Perret C,et al.Plateletactivating factor-acetylhydrolase and RAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease[J].Hum Mol Genet,2004;13(13):1341-1351.
[43]Sutton BS,Crosslin DR,Shah SH,Nelson SC,Bassil A,Hale AB,et al.Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7)gene and cardiovascular disease in case-control and family datasets[J].Hum Mol Genet,2008;17(9):1318-1328.
[44]Wilensky RL,Shi Y,Mohler ER,Hamamdzic D,Burgert ME,Li J,et al.Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development[J].Nat Med,2008;14(10):1059-1066.
[45]Helgadottir A,Manolescu A,Thorleifsson G,Gretarsdottir S,Jonsdottir H,Thorsteinsdottir U,et al.The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke[J].Nat Genet,2004;36(3):233-239.
[46]Helgadottir A,Gretarsdottir S,Clair DS,Manolescu A,Cheung J,Thorleifsson G,et al.Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population [J].Am J Hum Genet,2005;76(3):505-509.
[47]Girelli D,Martinelli N,Trabetti E,Olivieri O,Cavallari U,Malerba G,et al.ALOX5AP gene variants and risk of coronary artery disease:an angiography-based study[J].Eur J Hum Genet,2007;15(9):959-966.
[48]Linsel-Nitschke P,Gotz A,Medack A,Konig IR,Bruse P,Lieb W,et al.Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP)is associated with myocardial infarction in the German population [J].Clin Sci (Lond),2008;115(10):309-315.
[49]Dwyer JH,Allayee H,Dwyer KM,Fan J,Wu H,Mar R,et al.Arachidonate 5-lipoxygenase promoter genotype,dietary arachidonic acid,and atherosclerosis [J].N Engl J Med,2004;350(1 ):29-37.
[50]Helgadottir A,Manolescu A,Helgason A,Thorleifsson G,Thorsteinsdottir U,Gudbjartsson DF,et al.A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction [J].Nat Genet,2006;38(1):68-74.
[51]Qiu H,Gabrielsen A,Agardh HE,Wan M,Wetterholm A,Wong CH,et al.Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability [J].Proc Natl Acad Sci U S A,2006;103(21):8161-8166.
[52]Subbarao K,Jala VR,Mathis S,Suttles J,Zacharias W,Ahamed J,et al.Role of leukotriene B4 receptors in the development of atherosclerosis:potential mechanisms[J].Arterioscler Thromb Vase Biol,2004;24(2):369-375.
[53]Heller EA,Liu E,Tager AM,Sinha S,Roberts JD,Koehn SL,et al.Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment[J].Circulation,2005;112(4):578-586.
[54]Hakonarson H,Thorvaldsson S,Helgadottir A,Gudbjartsson D,Zink F,Andresdottir M,et al.Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction:a randomized trial[J].JAMA,2005;293(18):2245-2256.
[55]Funk CD.Leukotriene modifiers as potential therapeutics for cardiovascular disease[J].Nat Rev Drug Discov,2005;4(8):664-672.
[56]Ozaki K,Ohnishi Y,Iida A,Sekine A,Yamada R,Tsunoda T,et al.Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction[J].Nat Genet,2002;32(4):650-654.
[57]Ozaki K,Inoue K,Sato H,Iida A,Ohnishi Y,Sekine A,et al.Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro[J].Nature,2004;429(6987):72-75.
[58]Ozaki K,Sato H,Iida A,Mizuno H,Nakamura T,Miyamoto Y,et al.A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population [J].Nat Genet,2006;38(8):921-925.
[59]Hinohara K,Nakajima T,Sasaoka T,Sawabe M,Lee BS,Ban J,et al.Replication studies for the association of PSMA6 polymorphism with coronary artery disease in East Asian populations [J].J Hum Genet,2009;54(4):248-251.
[60]Liu X,Wang X,Shen Y,Wu L,Ruan X,Lindpaintner K,et al.The functional variant rs 1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population[J].Atherosclerosis,2009;.
[61]Bennet AM,van Maarle MC,Hallqvist J,Morgenstern R,Frostegard J,Wiman B,et al.Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction [J].Atherosclerosis,2006;187(2):408-414.
[62]Ozaki K,Sato H,Inoue K,Tsunoda T,Sakata Y,Mizuno H,et al.SNPs in BRAP associated with risk of myocardial infarction in Asian populations [J].Nat Genet,2009;41(3):329-333.
[63]Primo-Parmo SL,Sorenson RC,Teiber J,Du BNL.The human serum paraoxonase/arylesterase gene (PON1)is one member of a multigene family[J].Genomics,1996;33(3):498-507.
[64]Shih DM,Gu L,Xia YR,Navab M,Li WF,Hama S,et al.Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis[J].Nature,1998;394(6690):284-287.
[65]McElveen J,Mackness MI,Colley CM,Peard T,Warner S,Walker CH.Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction[J].Clin Chem,1986;32(4):671-673.
[66]Mackness B,Davies GK,Turkie W,Lee E,Roberts DH,Hill E,et al.Paraoxonase status in coronary heart disease:are activity and concentration more important than genotype[J]? Arterioscler Thromb Vase Biol,2001;21(9):1451-1457.
[67]Herrmann SM,Blanc H,Poirier O,Arveiler D,Luc G,Evans A,et al.The Gln/Arg polymorphism of human paraoxonase (PON 192)is not related to myocardial infarction in the ECTIM Study[J].Atherosclerosis,1996;126(2):299-303.
[68]Gardemann A,Philipp M,Hess K,Katz N,Tillmanns H,Haberbosch W.The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease[J].Atherosclerosis,2000;152(2):421-431.
[69]Imai Y,Morita H,Kuiihara H,Sugiyama T,Kato N,Ebihara A,et al.Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases[J].Atherosclerosis,2000;149(2):435-442.
[70]Jarvik GP,Rozek LS,Brophy VH,Hatsukami TS,Richter RJ,Schellenberg GD,et al.Paraoxonase (PON1)phenotype is a better predictor of vascular disease than is PONl(192)or P0N1(55)genotype[J].Arterioscler Thromb Vase Biol,2000;20(11):2441-2447.
[71]Garin MC,James RW,Dussoix P,Blanche H,Passa P,Froguel P,et al.Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme.A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes[J].J Clin Invest,1997;99(1):62-66.
[72]Wang X,Fan Z,Huang J,Su S,Yu Q,Zhao J,et al.Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population [J].Arterioscler Thromb Vase Biol,2003;23(2):328-334.
[73]Leviev I,James RW.Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations [J].Arterioscler Thromb Vase Biol,2000;20(2):516-521.
[74]Leviev I,Righetti A,James RW.Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease[J].J Mol Med,2001;79(8):457-463.
[75]yong Su S,hong Chen J,feng Huang J,ling Wang X,gong Zhao J,Shen Y,et al.Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women[J].Chin Med J (Engl),2005;118(14):1167-1174.
[76]James RW,Leviev I,Ruiz J,Passa P,Froguel P,Garin MC.Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients[J].Diabetes,2000;49(8):1390-1393.
[77]Ng CJ,Wadleigh DJ,Gangopadhyay A,Hama S,Grijalva VR,Navab M,et al.Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein[J].J Biol Chem,2001;276(48):44444-44449.
[78]Reddy ST,Wadleigh DJ,Grijalva V,Ng C,Hama S,Gangopadhyay A,et al.Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids[J].Arterioscler Thromb Vase Biol,2001;21(4):542-547.
[79]Sanghera DK,Aston CE,Saha N,Kamboh MI.DNA polymorphisms in two paraoxonase genes (PON1 and PON2)are associated with the risk of coronary heart disease[J].Am J Hum Genet,1998;62(1):36-44.
[80]Martinelli N,Girelli D,Olivieri O,Stranieri C,Trabetti E,Pizzolo F,et al.Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction [J].Eur J Clin Invest,2004;34(1):14-20.
[81]Saeed M,Iqbal MP,Yousuf FA,Perveen S,Shafiq M,Sajid J,et al.Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population[J].Clin Genet,2007;71(3):238-244.
[82]Mach F,Schonbeck U,Sukhova GK,Bourcier T,Bonnefoy JY,Pober JS,et al.Functional CD40 ligand is expressed on human vascular endothelial cells,smooth muscle cells,and macrophages:implications for CD40-CD40 ligand signaling in atherosclerosis[J].Proc Natl Acad Sci USA,1997;94(5):1931-1936.
[83]Mach F,Schonbeck U,Sukhova GK,Atkinson E,Libby P.Reduction of atherosclerosis in mice by inhibition of CD40 signalling[J].Nature,1998;394(6689):200-203.
[84]Lutgens E,Gorelik L,Daemen MJ,de Muinck ED,Grewal IS,Koteliansky VE,et al.Requirement for CD154 in the progression of atherosclerosis [J].Nat Med,1999;5(11):1313-1316.
[85]Aukrust P,Muller F,Ueland T,Berget T,Aaser E,Brunsvig A,et al.Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina.Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes [J].Circulation,1999;100(6):614-620.
[86]Schonbeck U,Varo N,Libby P,Buring J,Ridker PM.Soluble CD40L and cardiovascular risk in women[J].Circulation,2001;104(19):2266-2268.
[87]Heeschen C,Dimmeler S,Hamm CW,van den Brand MJ,Boersma E,Zeiher AM,et al.Soluble CD40 ligand in acute coronary syndromes[J].N Engl J Med,2003;348(12):1104-1111.
[88]Cipollone F,Ferri C,Desideri G,Paloscia L,Materazzo G,Mascellanti M,et al.Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty [J].Circulation,2003;108(22):2776-2782.
[89]Schonbeck U,Libby P.CD40 signaling and plaque instability [J].Circ Res,2001;89(12):1092-1103.
[90]Inwald DP,McDowall A,Peters MJ,Callard RE,Klein NJ.CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation [J].Circ Res,2003;92(9):1041-1048.
[91]Schonbeck U,Gerdes N,Varo N,Reynolds RS,Horton DB,Bavendiek U,et al.Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells[J].Circulation,2002;106(23):2888-2893.
[92]Malarstig A,Lindahl B,Wallentin L,Siegbahn A.Soluble CD40L levels are regulated by the-3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome[J].Arterioscler Thromb Vase Biol,2006;26(7):1667-1673.
[93]Burdon KP,Langefeld CD,Beck SR,Wagenknecht LE,Carr JJ,Rich SS,et al.Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS)[J].Am Heart J,2006;151(3):706-711.
[94]Yoshikawa Y,Satoh T,Tamura T,Wei P,Bilasy SE,Edamatsu H,et al.The M-Ras-RA-GEF-2-Rapl pathway mediates tumor necrosis factor-alpha dependent regulation of integrin activation in splenocytes[J].MolBiol Cell,2007;18(8):2949-2959.
[95]Ellsworth DL,Bielak LF,Turner ST,Sheedy PF,Boerwinkle E,Peyser PA.Genderand age-dependent relationships between the E-selectin S128R polymorphism and coronary artery calcification[J].JMolMed,2001;79(7):390-398.
[96]Tregouet DA,Barbaux S,Escolano S,Tahri N,Golmard JL,Tiret L,et al.Specific haplotypes of the P-selectin gene are associated with myocardial infarction[J].Hum Mol Genet,2002;11(17):2015-2023.
[97]Cipollone F,Toniato E,Martinotti S,Fazia M,Iezzi A,Cuccurullo C,et al.A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke[J].JAMA,2004;291(18):2221-2228.
[98]Koch W,Kastrati A,Bottiger C,Mehilli J,von Beckerath N,Schomig A.Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction[J].Atherosclerosis,2001;159(1):137-144.
[99]Iacoviello L,Castelnuovo AD,Gattone M,Pezzini A,Assanelli D,Lorenzet R,et al.Polymorphisms of the interleukin-lbeta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro[J].Arterioscler Thromb Vase Biol,2005;25(1):222-227.
[100]Moatti D,Faure S,Fumeron F,el W Amara M,Seknadji P,McDermott DH,et al.Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease[J].Blood,2001;97(7):1925-1928.
[101]Gonzalez P,Alvarez R,Batalla A,Reguero JR,Alvarez V,Astudillo A,et al.Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction [J].Genes Immun,2001;2(4):191-195.
[102]Hubacek JA,Rothe G,Pit'ha J,Skodov(?)Z,Stanek V,Poledne R,et al.C(-260)→T polymorphism in the promoter of the CD 14 monocyte receptor gene as a risk factor for myocardial infarction[J].Circulation,1999;99(25):3218-3220.
[103]Iovannisci DM,Lammer EJ,Steiner L,Cheng S,Mahoney LT,Davis PH,et al.Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women:the Muscatine Study[J].Arterioscler Thromb Vasc Biol,2007;27(2):394-399.
[104]Szalai C,Fiist G,Duba J,Kramer J,Romics L,Prohdszka Z,et al.Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease[J].J Med Genet,2002;39(1):46-51.
[105]Yamada Y,Ichihara S,Fujimura T,Yokota M.Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men[J].Metabolism,1998;47(2):177-181.
[106]Howell WM,Ali S,Rose-Zerilli MJ,Ye S.VEGF polymorphisms and severity of atherosclerosis[J].J Med Genet,2005;42(6):485-490.
[107]Georges JL,Loukaci V,Poirier O,Evans A,Luc G,Arveiler D,et al.Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction:the ECTIM study.Etude Cas-T(?)moin de l'Infarctus du Myocarde[J].J Mol Med,2001;79(5-6):300-305.
[108]Serrato M,Marian AJ.A variant of human paraoxonase/arylesterase (HUMPONA)gene is a risk factor for coronary artery disease[J].J Clin Invest,1995;96(6):3005-3008.
[109]Edfeldt K,Bennet AM,Eriksson P,Frostegard J,Wiman B,Hamsten A,et al.Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction[J].Eur Heart J,2004;25(16):1447-1453.
[110]Terashima M,Akita H,Kanazawa K,Inoue N,Yamada S,Ito K,et al.Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction[J].Circulation,1999;99(21):2717-2719.
[111]Lundberg GA,Kellin A,Samnegard A,Lundman P,Tornvall P,Dimmeler S,et al.Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene[J].J Intern Med,2005;257(5):415-422.
[112]Szalai C,Duba J,Prohdszka Z,A K,Szabd T,Nagy B,et al.Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD).Coincidence of elevated Lp(a)and MCP-1-2518 G/G genotype in CAD patients[J].Atherosclerosis,2001;158(1):233-239.
[113]Wei H,Fang L,Chowdhury SH,Gong N,Xiong Z,Song J,et al.Platelet-endothelial cell adhesion molecule-1 gene polymorphism and its soluble level are associated with severe coronary artery stenosis in Chinese Singaporean[J].Clin Biochem,2004;37(12):1091-1097.
[114]Nikpoor B,Turecki G,Fournier C,Theroux P,Rouleau GA.A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians[J].Am Heart J,2001;142(2):336-339.
[115]Jiang H,Klein RM,Niederacher D,Du M,Marx R,Horlitz M,et al.C/T polymorphism of the intercellular adhesion molecule-1 gene (exon 6,codon 469).A risk factor for coronary heart disease and myocardial infarction[J].Int J Cardiol,2002;84(2-3):171-177.
[116]Morgan AR,Zhang B,Tapper W,Collins A,Ye S.Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease[J].J Mol Med,2003;81(5):321-326.
[117]Reinhard W,Stark K,Sedlacek K,Fischer M,Baessler A,Neureuther K,et al.Association between PPARalpha gene polymorphisms and myocardial infarction.Clin Sci (Lond),2008;115(10):301-308.
[118]Kardys I,Klaver CC,Despriet DD,Bergen AA,Uitterlinden AG,Hofman A,et al.A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction:the Rotterdam Study [J].J Am Coll Cardiol,2006;47(8):1568-1575.
[119]Ortlepp JR,Vesper K,Mevissen V,Schmitz F,Janssens U,Franke A,et al.Chemokine receptor (CCR2)genotype is associated with myocardial infarction and heart failure in patients under 65 years of age [J].J Mol Med,2003;81(6):363-367.
[1]Warnes G,Gorjanc G,Leisch F,Man M.genetics:Population Genetics,2008.R package version 1.3.4.
[2]Clayton D.DGCgenetics:Additions/enhancements of the genetics package,2007.R package version 1.0.
[3]Sinnwell JP,Schaid DJ.haplo.stats:Statistical Analysis of Haplotypes with Traits and Covariates when Linkage Phase is Ambiguous,2009.R package version 1.4.3.
[4]Atkinson B,Therneau T.kinship:mixed-effects Cox models,sparse matrices,and modeling data from large pedigrees,2008.R package version 1.1.0-21.
[2]Kolodgie FD,Burke AP,Skorija KS,Ladich E,Kutys R,Makuria AT,et al.Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis [J].Arterioscler Thromb Vase Biol,2006;26(11):2523-2529.
[3]Stafforini DM,Numao T,Tsodikov A,Vaitkus D,Fukuda T,Watanabe N,et al.Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma[J].J Clin Invest,1999;103(7):989-997.
[4]H(a|¨)kkinen T,Luoma JS,Hiltunen MO,Macphee CH,Milliner KJ,Patel L,et al.Lipoprotein-associated phospholipase A(2),platelet-activating factor acetylhydrolase,is expressed by macrophages in human and rabbit atherosclerotic lesions[J].Arterioscler Thromb Vase Biol,1999;19(12):2909-2917.
[5]Ballantyne CM,Hoogeveen RC,Bang H,Coresh J,Folsom AR,Heiss G,et al.Lipoprotein-associated phospholipase A2,high-sensitivity C-reactive protein,and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC)study[J].Circulation,2004;109(7):837-842.
[6]Koenig W,Twardella D,Brenner H,Rothenbacher D.Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors,markers of inflammation,renal function,and hemodynamic stress[J].Arterioscler Thromb Vase Biol,2006;26(7):1586-1593.
[7]Oei HH,van der Meer JJM,Hofman A,Koudstaal PJ,Stijnen T,Breteler MMB,et al.Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke:the Rotterdam Study [J].Circulation,2005;111(5):570-575.
[8]Packard CJ,O'Reilly DS,Caslake MJ,McMahon AD,Ford I,Cooney J,et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.West of Scotland Coronary Prevention Study Group[J].N Engl J Med,2000;343(16):1148-1155.
[9]Sabatine MS,Morrow DA,O'Donoghue M,Jablonksi KA,Rice MM,Solomon S,et al.Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease [J].Arterioscler Thromb Vasc Biol,2007;27(11):2463-2469.
[10]Yamada Y,Ichihara S,Fujimura T,Yokota M.Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men [J].Metabolism,1998;47(2):177-181.
[11]Yamada Y,Yoshida H,Ichihara S,Imaizumi T,Satoh K,Yokota M.Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH)activity and PAFAH genotype,age,and atherosclerosis in a Japanese population[J].Atherosclerosis,2000;150(1):209-216.
[12]Zhang SY,Shibata H,Karino K,Wang BY,Kobayashi S,Masuda J,et al.Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population[J].Hypertens Res,2007;30(5):403-409.
[13]Hiramoto M,Yoshida H,Imaizumi T,Yoshimizu N,Satoh K.A mutation in plasma platelet-activating factor acetylhydrolase (Va1279→Phe)is a genetic risk factor for stroke[J].Stroke,1997;28(12):2417-2420.
[14]Jang Y,Kim OY,Koh SJ,Chae JS,Ko YG,Kim JY,et al.The Va1279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men[J].J Clin Endocrinol Metab,2006;91(9):3521-3527.
[15]Abuzeid AM,Hawe E,Humphries SE,Talmud PJ,Group HIFMECHS.Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe[J].Atherosclerosis,2003;168(2):283-288.
[16]Ninio E,Tregouet D,Carrier JL,Stengel D,Bickel C,Perret C,et al.Plateletactivating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease [J].Hum Mol Genet,2004;13(13):1341-1351.
[17]Kruse S,Mao XQ,Heinzmann A,Blattmann S,Roberts MH,Braun S,et al.The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma[J].Am J Hum Genet,2000;66(5):1522-1530.
[18]Wootton PT,Stephens JW,Hurel SJ,Durand H,Cooper J,Ninio E,et al.Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus[J].Atherosclerosis,2006;189(1):149-156.
[19]Schaid DJ,Rowland CM,Tines DE,Jacobson RM,Poland GA.Score tests for association between traits and haplotypes when linkage phase is ambiguous[J].Am J Hum Genet,2002;70(2):425-434.
[20]Persson M,Hedblad B,Nelson J J,Berglund G.Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects[J].Arterioscler Thromb Vase Biol,2007;27(6):1411-1416.
[21]Saougos VG,Tambaki AP,Kalogirou M,Kostapanos M,Gazi IF,Wolfert RL,et al.Differential effect of hypolipidemic drugs on lipoprotein-associated phosphohpase A2[J].Arterioscler Thromb Vase Biol,2007;27(10):2236-2243.
[22]Ross R.Atherosclerosis-an inflammatory disease[J].N Engl J Med,1999;340(2):115-126.
[23]Macphee CH.Lipoprotein-associated phosphohpase A2:a potential new risk factor for coronary artery disease and a therapeutic target[J].Curr Opin Pharmacol,2001;1(2):121-125.
[24]Brilakis ES,Khera A,McGuire DK,See R,Banerjee S,Murphy SA,et al.Influence of race and sex on lipoprotein-associated phosphohpase A2 levels:observations from the Dallas Heart Study[J].Atherosclerosis,2008;199(1):110-115.
[25]Sutton BS,Crosslin DR,Shah SH,Nelson SC,Bassil A,Hale AB,et al.Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7)gene and cardiovascular disease in case-control and family datasets[J].Hum Mol Genet,2008;17(9):1318-1328.
[26]Liu PY,Li YH,Wu HL,Chao TH,Tsai LM,Lin LJ,et al.Platelet-activating factoracetylhydrolase A379V (exon 11)gene polymorphism is an independent and func- tional risk factor for premature myocardial infarction[J].J Thromb Haemost,2006;4(5):1023-1028.
[27]Zondervan KT,Cardon LR.The complex interplay among factors that influence allelic association[J].Nat Rev Genet,2004;5(2):89-100.
[1]Bemelmans MH,van Tits LJ,Buurman WA.Tumor necrosis factor:function,release and clearance[J].Crit Rev Immunol,1996;16(1):1-11.
[2]Bochner BS,Luscinskas FW,Gimbrone MA,Newman W,Sterbinsky SA,Derse-Anthony CP,et al.Adhesion of human basophils,eosinophils,and neutrophils to interleukin 1-activated human vascular endothelial cells:contributions of endothelial cell adhesion molecules [J].J Exp Med,1991;173(6):1553-1557.
[3]Mantovani A.The interplay between primary and secondary cytokines.Cytokines involved in the regulation of monocyte recruitment[J].Drugs,1997;54 Suppl 1:15-23.
[4]Castell JV,Andus T,Kunz D,Heinrich PC.Interleukin-6.The major regulator of acute-phase protein synthesis in man and rat [J].Ann N Y Acad Sci,1989;557:87-99.
[5]Siwik DA,Chang DL,Colucci WS.Interleukin-1 beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro[J].Circ Res,2000;86(12):1259-1265.
[6]KahaFri VM,Chen YQ,Su MW,Ramirez F,Uitto J.Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1.Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels [J].J Clin Invest,1990;86(5):1489-1495.
[7]Zhang C,Zhang MX,Shen YH,Burks JK,Zhang Y,Wang J,et al.TNF-alpha suppresses prolyl-4-hydroxylase alphal expression via the ASKl-JNK-NonO pathway[J].Arterioscler Thromb Vase Biol,2007;27(8):1760-1767.
[8]Feingold KR,Grunfeld C.Role of cytokines in inducing hyperlipidemia[J].Diabetes,1992;41 Suppl 2:97-101.
[9]Hotamisligil GS,Shargill NS,Spiegelman BM.Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance [J].Science,1993;259(5091):87-91.
[10]Cesari M,Penninx BWJH,Newman AB,Kritchevsky SB,Nicklas BJ,Sutton-Tyrrell K,et al.Inflammatory markers and onset of cardiovascular events:results from the Health ABC study[JJ.Circulation,2003;108(19):2317-2322.
[11]Ridker PM,Rifai N,Pfeffer M,Sacks F,Lepage S,Braunwald E.Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction[J].Circulation,2000;101(18):2149-2153.
[12]Khot UN,Khot MB,Bajzer CT,Sapp SK,Ohman EM,Brener SJ,et al.Prevalence of conventional risk factors in patients with coronary heart disease[J].JAMA,2003;290(7):898-904.
[13]Haddy N,Sass C,Droesch S,Zaiou M,Siest G,Ponthieux A,et al.IL-6,TNF-alpha and atherosclerosis risk indicators in a healthy family population:the STANISLAS cohort[J].Atherosclerosis,2003;170(2):277-283.
[14]Abraham LJ,Kroeger KM.Impact of the-308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene:relevance to disease[J].J Leukoc Biol,1999;66(4):562-566.
[15]Kaluza W,Reuss E,Grossmann S,Hug R,Schopf RE,Galle PR,et al.Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism[J].J Invest Dermatol,2000;114(6):1180-1183.
[16]Hakkinen T,Luoma JS,Hiltunen MO,Macphee CH,Milliner KJ,Patel L,et al.Lipoprotein-associated phospholipase A(2),platelet-activating factor acetylhydrolase,is expressed by macrophages in human and rabbit atherosclerotic lesions [J].Arterioscler Thromb Vase Biol,1999;19(12):2909-2917.
[17]Szalai C,Fixst G,Duba J,Kramer J,Romics L,Prohdszka Z,et al.Association of polymorphisms and allelic combinations in the tumour necrosis factor-alphacomplement MHC region with coronary artery disease [J].J Med Genet,2002;39(1):46-51.
[18]Bidwell J,Keen L,Gallagher G,Kimberly R,Huizinga T,McDermott MF,et al.Cytokine gene polymorphism in human disease:on-line databases[J].Genes Immun,1999;1(1):3-19.
[19]Schaid DJ,Rowland CM,Tines DE,Jacobson RM,Poland GA.Score tests for association between traits and haplotypes when linkage phase is ambiguous[J].Am J Hum Genet,2002;70(2):425-434.
[20]Ackerman H,Usen S,Mott R,Richardson A,Sisay-Joof F,Katundu P,et al.Haplotypic analysis of the TNF locus by association efficiency and entropy [J].Genome Biol,2003;4(4):R24.
[21]Furuta M,Yano Y,Ito K,Gabazza EC,Katsuki A,Tanaka T,et al.Relationship of the tumor necrosis factor-alpha-308 A/G promoter polymorphism with insulin sensitivity and abdominal fat distribution in Japanese patients with type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2002;56(2):141-145.
[22]D'Alfonso S,Richiardi PM.A polymorphic variation in a putative regulation box of the TNFA promoter region [J].Immunogenetics,1994;39(2):150-154.
[23]Day CP,Grove J,Daly AK,Stewart MW,Avery PJ,Walker M.Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance[J].Diabetologia,1998;41(4):430-434.
[24]Culpan D,MacGowan SH,Ford JM,Nicoll JAR,Griffin WS,Dewar D,et al.Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease[J].Neurosci Lett,2003;350(1):61-65.
[25]Allen RA,Lee EM,Roberts DH,Park BK,Pirmohamed M.Polymorphisms in the TNF-alpha and TNF-receptor genes in patients with coronary artery disease[J].Eur J Clin Invest,2001;31(10):843-851.
[26]Vendrell J,Fernandez-Real JM,Gutierrez C,Zamora A,Simon I,Bardaji A,et al.A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308)is associated with coronary heart disease in type 2 diabetic patients[J].Atherosclerosis,2003;167(2):257-264.
[27]Bennet AM,van Maarle MC,Hallqvist J,Morgenstem R,Frostegard J,Wiman B,et al.Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction [J].Atherosclerosis,2006;187(2):408-414.
[28]Lee YH,Harley JB,Nath SK.Meta-analysis of TNF-alpha promoter-308 A/G polymorphism and SLE susceptibility [J].Eur J Hum Genet,2006;14(3):364-371.
[29]Wei Q,Doris PA,Pollizotto MV,Boerwinkle E,Jacobs DR,Siscovick DS,et al.Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis:interaction with cigarette smoking[J].Atherosclerosis,2007;190(1):26-34.
[1]Gu D,Reynolds K,Wu X,Chen J,Duan X,Muntner P,et al.Prevalence,awareness,treatment,and control of hypertension in china[J].Hypertension,2002;40(6):920-927.
[2]Libby P,Theroux P.Pathophysiology of coronary artery disease[J].Circulation,2005;111(25):3481-3488.
[3]Glagov S,Weisenberg E,Zarins CK,Stankunavicius R,Kolettis GJ.Compensatory enlargement of human atherosclerotic coronary arteries[J].N Engl J Med,1987;316(22):1371-1375.
[4]Clarkson TB,Prichard RW,Morgan TM,Petrick GS,Klein KP.Remodeling of coronary arteries in human and nonhuman primates[J].JAMA,1994;271(4):289-294.
[5]Tuzcu EM,Kapadia SR,Tutar E,Ziada KM,Hobbs RE,McCarthy PM,et al.High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults:evidence from intravascular ultrasound [J].Circulation,2001;103(22):2705-2710.
[6]Yokoya K,Takatsu H,Suzuki T,Hosokawa H,Ojio S,Matsubara T,et al.Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis:A study based on four serial coronary arteriograms per year[J].Circulation,1999;100(9):903-909.
[7]Falk E,Shah PK,Fuster V.Coronary plaque disruption [J].Circulation,1995;92(3):657-671.
[8]Virmani R,Burke AP,Farb A,Kolodgie FD.Pathology of the unstable plaque[J].Prog Cardiovasc Dis,2002;44(5):349-356.
[9]Libby P.Inflammation in atherosclerosis[J].Nature,2002;420(6917):868-874.
[10]Gimbrone MA.Vascular endothelium,hemodynamic forces,and atherogenesis[J].Am J Pathol,1999;155(1):1-5.
[11]Li H,Cybulsky MI,Gimbrone MA,Libby P.An atherogenic diet rapidly induces VCAM-1,a cytokine-regulatable mononuclear leukocyte adhesion molecule,in rabbit aortic endothelium [J].Arterioscler Thromb,1993;13(2):197-204.
[12]Collins T,Cybulsky MI.NF-kappaB:pivotal mediator or innocent bystander in atherogenesis[J]? J Clin Invest,2001;107(3):255-264.
[13]Gu L,Okada Y,Clinton SK,Gerard C,Sukhova GK,Libby P,et al.Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice[J].Mol Cell,1998;2(2):275-281.
[14]Boring L,Gosling J,Cleary M,Charo IF.Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis [J].Nature,1998;394(6696):894-897.
[15]Cyrus T,Witztum JL,Rader DJ,Tangirala R,Fazio S,Linton MF,et al.Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice[J].J Clin Invest,1999;103(11):1597-1604.
[16]Shih DM,Xia YR,Wang XP,Miller E,Castellani LW,Subbanagounder G,et al.Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis[J].J Biol Chem,2000;275(23):17527-17535.
[17]Suzuki H,Kurihara Y,Takeya M,Kamada N,Kataoka M,Jishage K,et al.A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection[J].Nature,1997;386(6622):292-296.
[18]Febbraio M,Podrez EA,Smith JD,Hajjar DP,Hazen SL,Hoff HF,et al.Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice[J].J Clin Invest,2000;105(8):1049-1056.
[19]Schonbeck U,Sukhova GK,Shimizu K,Mach F,Libby P.Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice[J].Proc Natl Acad Sci U S A,2000;97(13):7458-7463.
[20]Lange LA,Carlson CS,Hindorff LA,Lange EM,Walston J,Durda JP,et al.Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events[J].JAMA,2006;296(22):2703-2711.
[21]Reiner AP,Barber MJ,Guan Y,Ridker PM,Lange LA,Chasman DI,et al.Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein[J].Am J Hum Genet,2008;82(5):1193-1201.
[22]Ridker PM,Pare G,Parker A,Zee RYL,Danik JS,Buring JE,et al.Loci related to metabolic-syndrome pathways including LEPR,HNF1 A,IL6R,and GCKR associate with plasma C-reactive protein:the Women's Genome Health Study [J].Am J Hum Genet,2008;82(5):1185-1192.
[23]Erdmann J,Grosshennig A,Braund PS,Konig IR,Hengstenberg C,Hall AS,et al.New susceptibility locus for coronary artery disease on chromosome 3q22.3[J].Nat Genet,2009;41(3):280-282.
[24]Ridker PM,Cannon CP,Morrow D,Rifai N,Rose LM,McCabe CH,et al.Creactive protein levels and outcomes after statin therapy [J].N Engl J Med,2005;352(1 ):20-28.
[25]Cook NR,Buring JE,Ridker PM.The effect of including C-reactive protein in cardiovascular risk prediction models for women[J].Ann Intern Med,2006;145(1):21-29.
[26]Ridker PM,Paynter NP,Rifai N,Gaziano JM,Cook NR.C-reactive protein and parental history improve global cardiovascular risk prediction:the Reynolds Risk Score for men[J].Circulation,2008;118(22):2243-51,4p following 2251.
[27]Caslake MJ,Packard CJ,Suckling KE,Holmes SD,Chamberlain P,Macphee CH.Lipoprotein-associated phospholipase A(2),platelet-activating factor acetylhydrolase:a potential new risk factor for coronary artery disease[J].Atherosclerosis,2000;150(2):413-419.
[28]Manya H,Aoki J,Kato H,Ishii J,Hino S,Arai H,et al.Biochemical characterization of various catalytic complexes of the brain platelet-activating factor acetylhydrolase[J].J Biol Chem,1999;274(45):31827-31832.
[29]Watson AD,Navab M,Hama SY,Sevanian A,Prescott SM,Stafforini DM,et al.Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein [J].J Clin Invest,1995;95(2):774-782.
[30]Macphee CH,Nelson J,Zalewski A.Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target[J].Curr Opin Pharmacol,2006;6(2):154-161.
[31]Zalewski A,Macphee C.Role of lipoprotein-associated phospholipase A2 in atherosclerosis:biology,epidemiology,and possible therapeutic target[J].Arterioscler Thromb Vase Biol,2005;25(5):923-931.
[32]Packard CJ,O'Reilly DS,Caslake MJ,McMahon AD,Ford I,Cooney J,et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.West of Scotland Coronary Prevention Study Group[J].N Engl J Med,2000;343(16):1148-1155.
[33]Koenig W,Khuseyinova N,Lowel H,Trischler G,Meisinger C.Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population:results from the 14-year follow-up of a large cohort from southern Germany [J].Circulation,2004;110(14):1903-1908.
[34]Brilakis ES,McConnell JP,Lennon RJ,Elesber AA,Meyer JG,Berger PB.Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors,angiographic coronary artery disease,and major adverse events at follow-up[J].Eur Heart J,2005;26(2):137-144.
[35]Koenig W,Twardella D,Brenner H,Rothenbacher D.Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors,markers of inflammation,renal function,and hemodynamic stress[J].Arterioscler Thromb Vase Biol,2006;26(7):1586-1593.
[36]O'Donoghue M,Morrow DA,Sabatine MS,Murphy SA,McCabe CH,Cannon CP,et al.Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)trial[J].Circulation,2006;113(14):1745-1752.
[37]Jang Y,Kim OY,Koh SJ,Chae JS,Ko YG,Kim JY,et al.The Va1279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men[J].J Clin Endocrinol Metab,2006;91(9):3521-3527.
[38]Hou L,Chen S,Yu H,Lu X,Chen J,Wang L,et al.Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population:the Beijing atherosclerosis study[J].Hum Genet,2009;125(1):11-20.
[39]Sekuri C,Cam FS,Tengiz I,Ercan E,Bayturan O,Berdeli A.Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coro- nary artery disease in Turkish patients[J].Anadolu Kardiyol Derg,2006;6(2):132-134.
[40]Kruse S,Mao XQ,Heinzmann A,Blattmann S,Roberts MH,Braun S,et al.The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma[J].Am J Hum Genet,2000;66(5):1522-1530.
[41]Abuzeid AM,Hawe E,Humphries SE,Talmud PJ,Group HIFMECHS.Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe[J].Atherosclerosis,2003;168(2):283-288.
[42]Ninio E,Tregouet D,Carrier JL,Stengel D,Bickel C,Perret C,et al.Plateletactivating factor-acetylhydrolase and RAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease[J].Hum Mol Genet,2004;13(13):1341-1351.
[43]Sutton BS,Crosslin DR,Shah SH,Nelson SC,Bassil A,Hale AB,et al.Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7)gene and cardiovascular disease in case-control and family datasets[J].Hum Mol Genet,2008;17(9):1318-1328.
[44]Wilensky RL,Shi Y,Mohler ER,Hamamdzic D,Burgert ME,Li J,et al.Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development[J].Nat Med,2008;14(10):1059-1066.
[45]Helgadottir A,Manolescu A,Thorleifsson G,Gretarsdottir S,Jonsdottir H,Thorsteinsdottir U,et al.The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke[J].Nat Genet,2004;36(3):233-239.
[46]Helgadottir A,Gretarsdottir S,Clair DS,Manolescu A,Cheung J,Thorleifsson G,et al.Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population [J].Am J Hum Genet,2005;76(3):505-509.
[47]Girelli D,Martinelli N,Trabetti E,Olivieri O,Cavallari U,Malerba G,et al.ALOX5AP gene variants and risk of coronary artery disease:an angiography-based study[J].Eur J Hum Genet,2007;15(9):959-966.
[48]Linsel-Nitschke P,Gotz A,Medack A,Konig IR,Bruse P,Lieb W,et al.Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP)is associated with myocardial infarction in the German population [J].Clin Sci (Lond),2008;115(10):309-315.
[49]Dwyer JH,Allayee H,Dwyer KM,Fan J,Wu H,Mar R,et al.Arachidonate 5-lipoxygenase promoter genotype,dietary arachidonic acid,and atherosclerosis [J].N Engl J Med,2004;350(1 ):29-37.
[50]Helgadottir A,Manolescu A,Helgason A,Thorleifsson G,Thorsteinsdottir U,Gudbjartsson DF,et al.A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction [J].Nat Genet,2006;38(1):68-74.
[51]Qiu H,Gabrielsen A,Agardh HE,Wan M,Wetterholm A,Wong CH,et al.Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability [J].Proc Natl Acad Sci U S A,2006;103(21):8161-8166.
[52]Subbarao K,Jala VR,Mathis S,Suttles J,Zacharias W,Ahamed J,et al.Role of leukotriene B4 receptors in the development of atherosclerosis:potential mechanisms[J].Arterioscler Thromb Vase Biol,2004;24(2):369-375.
[53]Heller EA,Liu E,Tager AM,Sinha S,Roberts JD,Koehn SL,et al.Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment[J].Circulation,2005;112(4):578-586.
[54]Hakonarson H,Thorvaldsson S,Helgadottir A,Gudbjartsson D,Zink F,Andresdottir M,et al.Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction:a randomized trial[J].JAMA,2005;293(18):2245-2256.
[55]Funk CD.Leukotriene modifiers as potential therapeutics for cardiovascular disease[J].Nat Rev Drug Discov,2005;4(8):664-672.
[56]Ozaki K,Ohnishi Y,Iida A,Sekine A,Yamada R,Tsunoda T,et al.Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction[J].Nat Genet,2002;32(4):650-654.
[57]Ozaki K,Inoue K,Sato H,Iida A,Ohnishi Y,Sekine A,et al.Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro[J].Nature,2004;429(6987):72-75.
[58]Ozaki K,Sato H,Iida A,Mizuno H,Nakamura T,Miyamoto Y,et al.A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population [J].Nat Genet,2006;38(8):921-925.
[59]Hinohara K,Nakajima T,Sasaoka T,Sawabe M,Lee BS,Ban J,et al.Replication studies for the association of PSMA6 polymorphism with coronary artery disease in East Asian populations [J].J Hum Genet,2009;54(4):248-251.
[60]Liu X,Wang X,Shen Y,Wu L,Ruan X,Lindpaintner K,et al.The functional variant rs 1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population[J].Atherosclerosis,2009;.
[61]Bennet AM,van Maarle MC,Hallqvist J,Morgenstern R,Frostegard J,Wiman B,et al.Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction [J].Atherosclerosis,2006;187(2):408-414.
[62]Ozaki K,Sato H,Inoue K,Tsunoda T,Sakata Y,Mizuno H,et al.SNPs in BRAP associated with risk of myocardial infarction in Asian populations [J].Nat Genet,2009;41(3):329-333.
[63]Primo-Parmo SL,Sorenson RC,Teiber J,Du BNL.The human serum paraoxonase/arylesterase gene (PON1)is one member of a multigene family[J].Genomics,1996;33(3):498-507.
[64]Shih DM,Gu L,Xia YR,Navab M,Li WF,Hama S,et al.Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis[J].Nature,1998;394(6690):284-287.
[65]McElveen J,Mackness MI,Colley CM,Peard T,Warner S,Walker CH.Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction[J].Clin Chem,1986;32(4):671-673.
[66]Mackness B,Davies GK,Turkie W,Lee E,Roberts DH,Hill E,et al.Paraoxonase status in coronary heart disease:are activity and concentration more important than genotype[J]? Arterioscler Thromb Vase Biol,2001;21(9):1451-1457.
[67]Herrmann SM,Blanc H,Poirier O,Arveiler D,Luc G,Evans A,et al.The Gln/Arg polymorphism of human paraoxonase (PON 192)is not related to myocardial infarction in the ECTIM Study[J].Atherosclerosis,1996;126(2):299-303.
[68]Gardemann A,Philipp M,Hess K,Katz N,Tillmanns H,Haberbosch W.The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease[J].Atherosclerosis,2000;152(2):421-431.
[69]Imai Y,Morita H,Kuiihara H,Sugiyama T,Kato N,Ebihara A,et al.Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases[J].Atherosclerosis,2000;149(2):435-442.
[70]Jarvik GP,Rozek LS,Brophy VH,Hatsukami TS,Richter RJ,Schellenberg GD,et al.Paraoxonase (PON1)phenotype is a better predictor of vascular disease than is PONl(192)or P0N1(55)genotype[J].Arterioscler Thromb Vase Biol,2000;20(11):2441-2447.
[71]Garin MC,James RW,Dussoix P,Blanche H,Passa P,Froguel P,et al.Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme.A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes[J].J Clin Invest,1997;99(1):62-66.
[72]Wang X,Fan Z,Huang J,Su S,Yu Q,Zhao J,et al.Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population [J].Arterioscler Thromb Vase Biol,2003;23(2):328-334.
[73]Leviev I,James RW.Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations [J].Arterioscler Thromb Vase Biol,2000;20(2):516-521.
[74]Leviev I,Righetti A,James RW.Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease[J].J Mol Med,2001;79(8):457-463.
[75]yong Su S,hong Chen J,feng Huang J,ling Wang X,gong Zhao J,Shen Y,et al.Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women[J].Chin Med J (Engl),2005;118(14):1167-1174.
[76]James RW,Leviev I,Ruiz J,Passa P,Froguel P,Garin MC.Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients[J].Diabetes,2000;49(8):1390-1393.
[77]Ng CJ,Wadleigh DJ,Gangopadhyay A,Hama S,Grijalva VR,Navab M,et al.Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein[J].J Biol Chem,2001;276(48):44444-44449.
[78]Reddy ST,Wadleigh DJ,Grijalva V,Ng C,Hama S,Gangopadhyay A,et al.Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids[J].Arterioscler Thromb Vase Biol,2001;21(4):542-547.
[79]Sanghera DK,Aston CE,Saha N,Kamboh MI.DNA polymorphisms in two paraoxonase genes (PON1 and PON2)are associated with the risk of coronary heart disease[J].Am J Hum Genet,1998;62(1):36-44.
[80]Martinelli N,Girelli D,Olivieri O,Stranieri C,Trabetti E,Pizzolo F,et al.Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction [J].Eur J Clin Invest,2004;34(1):14-20.
[81]Saeed M,Iqbal MP,Yousuf FA,Perveen S,Shafiq M,Sajid J,et al.Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population[J].Clin Genet,2007;71(3):238-244.
[82]Mach F,Schonbeck U,Sukhova GK,Bourcier T,Bonnefoy JY,Pober JS,et al.Functional CD40 ligand is expressed on human vascular endothelial cells,smooth muscle cells,and macrophages:implications for CD40-CD40 ligand signaling in atherosclerosis[J].Proc Natl Acad Sci USA,1997;94(5):1931-1936.
[83]Mach F,Schonbeck U,Sukhova GK,Atkinson E,Libby P.Reduction of atherosclerosis in mice by inhibition of CD40 signalling[J].Nature,1998;394(6689):200-203.
[84]Lutgens E,Gorelik L,Daemen MJ,de Muinck ED,Grewal IS,Koteliansky VE,et al.Requirement for CD154 in the progression of atherosclerosis [J].Nat Med,1999;5(11):1313-1316.
[85]Aukrust P,Muller F,Ueland T,Berget T,Aaser E,Brunsvig A,et al.Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina.Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes [J].Circulation,1999;100(6):614-620.
[86]Schonbeck U,Varo N,Libby P,Buring J,Ridker PM.Soluble CD40L and cardiovascular risk in women[J].Circulation,2001;104(19):2266-2268.
[87]Heeschen C,Dimmeler S,Hamm CW,van den Brand MJ,Boersma E,Zeiher AM,et al.Soluble CD40 ligand in acute coronary syndromes[J].N Engl J Med,2003;348(12):1104-1111.
[88]Cipollone F,Ferri C,Desideri G,Paloscia L,Materazzo G,Mascellanti M,et al.Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty [J].Circulation,2003;108(22):2776-2782.
[89]Schonbeck U,Libby P.CD40 signaling and plaque instability [J].Circ Res,2001;89(12):1092-1103.
[90]Inwald DP,McDowall A,Peters MJ,Callard RE,Klein NJ.CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation [J].Circ Res,2003;92(9):1041-1048.
[91]Schonbeck U,Gerdes N,Varo N,Reynolds RS,Horton DB,Bavendiek U,et al.Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells[J].Circulation,2002;106(23):2888-2893.
[92]Malarstig A,Lindahl B,Wallentin L,Siegbahn A.Soluble CD40L levels are regulated by the-3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome[J].Arterioscler Thromb Vase Biol,2006;26(7):1667-1673.
[93]Burdon KP,Langefeld CD,Beck SR,Wagenknecht LE,Carr JJ,Rich SS,et al.Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS)[J].Am Heart J,2006;151(3):706-711.
[94]Yoshikawa Y,Satoh T,Tamura T,Wei P,Bilasy SE,Edamatsu H,et al.The M-Ras-RA-GEF-2-Rapl pathway mediates tumor necrosis factor-alpha dependent regulation of integrin activation in splenocytes[J].MolBiol Cell,2007;18(8):2949-2959.
[95]Ellsworth DL,Bielak LF,Turner ST,Sheedy PF,Boerwinkle E,Peyser PA.Genderand age-dependent relationships between the E-selectin S128R polymorphism and coronary artery calcification[J].JMolMed,2001;79(7):390-398.
[96]Tregouet DA,Barbaux S,Escolano S,Tahri N,Golmard JL,Tiret L,et al.Specific haplotypes of the P-selectin gene are associated with myocardial infarction[J].Hum Mol Genet,2002;11(17):2015-2023.
[97]Cipollone F,Toniato E,Martinotti S,Fazia M,Iezzi A,Cuccurullo C,et al.A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke[J].JAMA,2004;291(18):2221-2228.
[98]Koch W,Kastrati A,Bottiger C,Mehilli J,von Beckerath N,Schomig A.Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction[J].Atherosclerosis,2001;159(1):137-144.
[99]Iacoviello L,Castelnuovo AD,Gattone M,Pezzini A,Assanelli D,Lorenzet R,et al.Polymorphisms of the interleukin-lbeta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro[J].Arterioscler Thromb Vase Biol,2005;25(1):222-227.
[100]Moatti D,Faure S,Fumeron F,el W Amara M,Seknadji P,McDermott DH,et al.Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease[J].Blood,2001;97(7):1925-1928.
[101]Gonzalez P,Alvarez R,Batalla A,Reguero JR,Alvarez V,Astudillo A,et al.Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction [J].Genes Immun,2001;2(4):191-195.
[102]Hubacek JA,Rothe G,Pit'ha J,Skodov(?)Z,Stanek V,Poledne R,et al.C(-260)→T polymorphism in the promoter of the CD 14 monocyte receptor gene as a risk factor for myocardial infarction[J].Circulation,1999;99(25):3218-3220.
[103]Iovannisci DM,Lammer EJ,Steiner L,Cheng S,Mahoney LT,Davis PH,et al.Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women:the Muscatine Study[J].Arterioscler Thromb Vasc Biol,2007;27(2):394-399.
[104]Szalai C,Fiist G,Duba J,Kramer J,Romics L,Prohdszka Z,et al.Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease[J].J Med Genet,2002;39(1):46-51.
[105]Yamada Y,Ichihara S,Fujimura T,Yokota M.Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men[J].Metabolism,1998;47(2):177-181.
[106]Howell WM,Ali S,Rose-Zerilli MJ,Ye S.VEGF polymorphisms and severity of atherosclerosis[J].J Med Genet,2005;42(6):485-490.
[107]Georges JL,Loukaci V,Poirier O,Evans A,Luc G,Arveiler D,et al.Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction:the ECTIM study.Etude Cas-T(?)moin de l'Infarctus du Myocarde[J].J Mol Med,2001;79(5-6):300-305.
[108]Serrato M,Marian AJ.A variant of human paraoxonase/arylesterase (HUMPONA)gene is a risk factor for coronary artery disease[J].J Clin Invest,1995;96(6):3005-3008.
[109]Edfeldt K,Bennet AM,Eriksson P,Frostegard J,Wiman B,Hamsten A,et al.Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction[J].Eur Heart J,2004;25(16):1447-1453.
[110]Terashima M,Akita H,Kanazawa K,Inoue N,Yamada S,Ito K,et al.Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction[J].Circulation,1999;99(21):2717-2719.
[111]Lundberg GA,Kellin A,Samnegard A,Lundman P,Tornvall P,Dimmeler S,et al.Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene[J].J Intern Med,2005;257(5):415-422.
[112]Szalai C,Duba J,Prohdszka Z,A K,Szabd T,Nagy B,et al.Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD).Coincidence of elevated Lp(a)and MCP-1-2518 G/G genotype in CAD patients[J].Atherosclerosis,2001;158(1):233-239.
[113]Wei H,Fang L,Chowdhury SH,Gong N,Xiong Z,Song J,et al.Platelet-endothelial cell adhesion molecule-1 gene polymorphism and its soluble level are associated with severe coronary artery stenosis in Chinese Singaporean[J].Clin Biochem,2004;37(12):1091-1097.
[114]Nikpoor B,Turecki G,Fournier C,Theroux P,Rouleau GA.A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians[J].Am Heart J,2001;142(2):336-339.
[115]Jiang H,Klein RM,Niederacher D,Du M,Marx R,Horlitz M,et al.C/T polymorphism of the intercellular adhesion molecule-1 gene (exon 6,codon 469).A risk factor for coronary heart disease and myocardial infarction[J].Int J Cardiol,2002;84(2-3):171-177.
[116]Morgan AR,Zhang B,Tapper W,Collins A,Ye S.Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease[J].J Mol Med,2003;81(5):321-326.
[117]Reinhard W,Stark K,Sedlacek K,Fischer M,Baessler A,Neureuther K,et al.Association between PPARalpha gene polymorphisms and myocardial infarction.Clin Sci (Lond),2008;115(10):301-308.
[118]Kardys I,Klaver CC,Despriet DD,Bergen AA,Uitterlinden AG,Hofman A,et al.A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction:the Rotterdam Study [J].J Am Coll Cardiol,2006;47(8):1568-1575.
[119]Ortlepp JR,Vesper K,Mevissen V,Schmitz F,Janssens U,Franke A,et al.Chemokine receptor (CCR2)genotype is associated with myocardial infarction and heart failure in patients under 65 years of age [J].J Mol Med,2003;81(6):363-367.
[1]Warnes G,Gorjanc G,Leisch F,Man M.genetics:Population Genetics,2008.R package version 1.3.4.
[2]Clayton D.DGCgenetics:Additions/enhancements of the genetics package,2007.R package version 1.0.
[3]Sinnwell JP,Schaid DJ.haplo.stats:Statistical Analysis of Haplotypes with Traits and Covariates when Linkage Phase is Ambiguous,2009.R package version 1.4.3.
[4]Atkinson B,Therneau T.kinship:mixed-effects Cox models,sparse matrices,and modeling data from large pedigrees,2008.R package version 1.1.0-21.